Randomized controlled trial

Scientists want to find what works best.

They split people into two groups. One group gets a new medicine. The other group does not. This helps us learn the truth.

Sometimes, people do not know which group they are in. This is called blinding. It keeps the test fair.

They use this to test things like food or tools. It can even be used in schools. This helps us know if a new way works.

These tests help keep people safe. They show us how to stay healthy.

Scientists want to know if a new idea really works. They use a special test called a randomized controlled trial. We often call this an RCT.

In an RCT, researchers split people into groups. One group gets the new treatment. This might be a new drug or a new diet. The other group is the control group. They might get the old treatment or a placebo. A placebo is something that looks real but has no medicine.

To keep things fair, scientists use randomness. They do not pick who goes into which group. They use chance to decide. This helps make sure the groups are similar. It stops bias, which is when one side is favored.

Sometimes, the test is "blind." This means the people in the study do not know their group. Even the researchers might not know. This helps keep the results honest.

Many people helped build these tests. James Lind used them to study scurvy in 1747. Austin Bradford Hill helped create the modern RCT. These tests are now the gold standard for medicine. They help us find the safest ways to stay healthy.

{ "text": "Scientists often need to know if a new idea truly works. They use a special test called a randomized controlled trial, or an RCT.

This test helps them check if a treatment is safe or helpful. One group of people receives the new intervention, like a drug or a diet. Another group serves as the control group. They might receive the usual care or a placebo. A placebo is something that looks real but has no medicine inside. This design helps scientists see the real effect of the new idea.\n\nTo make the test fair, researchers use randomness to pick groups. They do not choose who gets the new treatment. Instead, they use chance to decide. This helps stop bias, which is when one side is favored. Bias can happen if groups are not similar at the start. Randomness balances out things we know and things we do not know. This makes the comparison between the two groups very strong. If the trial is well-designed, it can provide great evidence for health.

\n\nMany people helped develop these important scientific methods over time. In 1648, Jan Baptist van Helmont proposed a trial for fever. Later, James Lind conducted a famous trial for scurvy in 1747. In 1784, a commission used the first blind experiment to study mesmerism. Scientists like Claude Bernard also suggested that researchers should not know the results early. In 1907, W. H. R. Rivers and H. N. Webber published a study on caffeine. Austin Bradford Hill is credited with conceiving the modern RCT in 1948.

\n\nThere are different ways to set up these scientific studies. A parallel-group trial is the most common kind used today. In this type, each person stays in just one group. A crossover trial is different because people switch groups over time. Some trials use clusters, like whole schools or villages, instead of single people. Another type is the factorial trial, which tests combinations of treatments. In 2006, a study showed that 78% of trials were parallel-group. These different designs help scientists answer many different kinds of questions.

\n\nUsing these trials requires following

A randomized controlled trial, or RCT, is a specific type of scientific experiment. Researchers use this design to evaluate the efficacy or safety of an intervention. An intervention can be a new drug, a surgical procedure, a medical device, a diet, or a diagnostic test. The goal is to determine if the intervention actually causes a specific effect on human health. By using this method, scientists can minimize bias and reduce the influence of confounding factors. These factors are unknown or known differences between people that might change the study results.

The mechanism of an RCT relies on the random allocation of participants into comparison groups. At least one group receives the intervention being studied, which is called the experimental group. Another group receives an alternative treatment, standard care, or a placebo. A placebo is an inactive substance that looks like the real treatment. This design helps isolate the actual physiological effects of the treatment from psychological biases. To prevent bias, researchers often use blinding. Blinding means participants do not know which group they are in. Ideally, this extends to researchers, technicians, and data analysts as well.

There are several distinct ways to design these trials. The most common is the parallel-group design, where each participant stays in one assigned group. In a crossover trial, participants receive different treatments in a random sequence over time. Some researchers use cluster trials, which involve pre-existing groups like schools or villages. Factorial trials allow participants to receive combinations of different interventions. A study of 616 RCTs in PubMed in 2006 found that 78% were parallel-group trials. Other designs include crossover trials at 16%, while cluster and factorial trials each made up 2%.

The history of these methods spans several centuries. In 1648, Jan Baptist van Helmont proposed a trial to test two different fever treatments. In 1747, James Lind conducted the first reported clinical trial to identify a treatment for scurvy. The first blind experiment occurred in 1784 when the French Royal Commission on Animal Magnetism investigated mesmerism. In the late 19th century, Claude Bernard advocated for blinding researchers to protect objectivity. By the early 20th century, randomized experiments appeared in psychology and agriculture. Austin Bradford Hill is credited with conceiving the modern RCT in a 1948 paper on streptomycin.

Modern RCTs are highly significant in the field of evidence-based medicine. They are considered a gold standard for clinical trials because they provide compelling evidence. By the late 20th century, they became the standard for rational therapeutics. The scale of this research is massive. As of 2004, the Cochrane Library contained more than 150,000 RCTs. To ensure quality, scientists use the Consolidated Standards of Reporting Trials (CONSORT) Statements. These standards were published in 1996, 2001, and 2010 to improve how trials are reported.

Ethics play a vital role in how these trials are conducted. Participants usually provide informed consent, but some may experience therapeutic misconception. This happens when a person believes the research is actually personalized treatment. Placebo-controlled trials can be unethical if withholding treatment might cause harm or death. In such cases, researchers use active-controlled trials or crossover trials instead. Scientists also use the principle of equipoise, which is genuine uncertainty about which treatment is better. Balancing patient well-being with the need for scientific data remains a complex challenge.

RCTs connect to many broader scientific and regulatory systems. For example, the International Committee of Medical Journal Editors requires trial registration for most publications. This rule began for trials starting enrollment after July 1, 2005. Researchers also classify trials by their purpose, such as explanatory or pragmatic. Explanatory trials test efficacy under highly controlled research settings. Pragmatic trials test effectiveness in everyday practice with more flexible conditions. These different approaches help inform real-world medical decisions and improve global health standards.